Skip to content

About Partners Innovation


Partners HealthCare Innovation

Partners HealthCare Innovation coordinates industrial relationships and IP management across Partners HealthCare, Brigham and Women’s Hospital, Massachusetts General Hospital, and McLean Hospital.

Partners Innovation is a cohesive, coordinated group servicing medical inventors, thought-leaders, entrepreneurs and industry. Our goal is to take medical inventions and innovations discovered by Partners HealthCare researchers and provide the appropriate support and infrastructure to allow technology development, commercialization and, ultimately, the development of products to benefit patients.

The team has backgrounds in technology licensing, patenting, bench research, finance, funding, business, law and start-ups.

Primary Functions

Primary functions in converting invention to innovation:

  • Business development
  • Company creation
  • Industry collaborations
  • Innovation management
  • International consulting
  • Licensing
  • Research translations strategy and funding
  • Technology marketing
  • Venture investing
  • Workforce capacity building for commercial collaborations

Our Mission

Innovation is the 120-person business development unit of Partners HealthCare responsible for the worldwide commercial application of the unique capabilities and discoveries of Partners' 74,000 employees. Innovation supports the research requirements of its 6,200 Harvard Medical School faculty and research hospitals. It has responsibility for industry collaborations, venture investing, international consulting, licensing, innovation management, company creation, technology marketing, open innovation alliances, and workforce development.

Licensing Partnerships

Partners Innovation is a division of Partners HealthCare that coordinates commercialization for Brigham and Women’s Hospital and Massachusetts General Hospital.

We work with investors and companies to license medical technologies in diagnostics, medical devices, research tools, medical software, therapeutics and vaccines.

Below is a representative list of companies that have licensed our technologies.



One of the unique strengths of our researchers across Partners HealthCare is their ability to seek and recognize relationships between biology and disease propensity, progression, or response to a particular therapy. This leads to better diagnostics that are at the cutting edge of the personalized medicine revolution.

MGH researchers were the first to recognize a relationship between EGFR mutations in lung cancer patients and a dramatic response for targeted therapy. BWH cardiologists were the first to recognize that measuring CRP, a biological marker for inflammation, can identify patients at risk of cardiovascular events in the absence of other risk factors, such as high cholesterol. Both of these examples, and others have become successful commercial diagnostic tests, helping to identify patients for appropriate life saving drug therapy.

  • Athena Diagnostics
  • AviaraDx
  • Consumer Genetics
  • Correlagen
  • Critical Care Diagnostics Inc.
  • Dysautonomia Foundation
  • Fluoropharma
  • GenProbe
  • Genzyme Corp
  • Nymox
  • Roche Diagnostics

Medical Devices

  • Biomet
  • Candela Corporation
  • Cook Inc
  • Freedom-2
  • General Electric
  • Gillette
  • GPB Scientfic, LLC
  • Hologic
  • Lumenis
  • Medrad
  • Neuroptix
  • Nidek
  • Palomar Medical Technologies
  • Pluromed
  • Reliant Technologies, Inc.
  • Terumo
  • Zimmer

Research Tool/Screening

  • Amersham Biosciences UK Ltd.
  • BD Biosciences
  • Bristol Myers Squibb Company
  • Diagnostic Systems Laboratory
  • General Electric Co.
  • Invitrogen Corporation
  • Millipore Corporation
  • Pharmigen
  • Phillips International
  • Siemens AG
  • Tyco Healthcare Group LP
  • Upstate Biotechnology Inc


In an effort to ensure intellectual property is made available to the broader healthcare community, Partners has expanded their intellectual property licensing offerings to include software developed internally. Partners makes a substantial financial and intellectual commitment in developing software for internal use. The types of software development are broad and varied to meet the ever-changing requirements of a large, integrated, healthcare delivery system.

Some of the models Partners uses to commercialize software include end user licenses, exclusive licenses, and joint ventures. The ultimate decision for which model to pursue depends on the particular software and strategic vision for commercialization.

  • CorTechs, Inc.
  • Ion Beam Applications
  • Medicalis Corporation


Research conducted at PHS hospitals has lead to a long list of therapeutic products that are either making their way through the development process with industry partners, or have become FDA approved products and are treating disease and saving lives on a daily basis.

Notable examples of therapeutics from the PHS labs include novel anti inflammatory agents called Resolvins that mimic the beneficial effects of Omega 3 fatty acids, Enbrel, a mainstay in the treatment of autoimmune disorders such as rheumatoid arthritis and psoriasis, and Pepsid Complete, a well known over the counter heartburn treatment.

Therapeutic discoveries from the PHS research hospitals span a wide range of applications, from small molecules, to biologics and vaccines covering almost every therapeutic area or disease.

  • Amgen
  • Aridis Pharmaceuticals, LLC
  • Bayer Healthcare Pharmaceuticals
  • Biogen Idec Corporation
  • Cardiopharma, Inc.
  • CellAct Pharma GmbH
  • Celladon
  • Fresenius AB
  • Ikaria, Linde AG
  • Insightec
  • Johnson and Johnson
  • LigoCyte Pharmaceuticals Inc.
  • Marinus Pharmaceuticals
  • Merck Consumer Pharm.
  • Mersana
  • NanoCor
  • Novartis
  • NPS Pharmaceuticals
  • Oxford Biomedica
  • Photopharmica Ltd.
  • Prestwick Pharmaceuticals
  • Purdue Neurosciences
  • QLT
  • Resolvyx Pharmaceuticals
  • Scios/Novo Nordisk
  • Synovex Inc.
  • Transition Therapeutics Inc.
  • Vanda Pharmaceuticals
  • Wyeth